Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

NCT07316010 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Large B-cell Lymphoma

Interventions

PROCEDURE: Leukapheresis
DRUG: Lymphodepleting Chemotherapy

Sponsor

M.D. Anderson Cancer Center